Free Trial
NASDAQ:AXGN

AxoGen (AXGN) Stock Price, News & Analysis

AxoGen logo
$16.14 -0.08 (-0.49%)
Closing price 08/29/2025 04:00 PM Eastern
Extended Trading
$16.14 0.00 (0.00%)
As of 08/29/2025 06:08 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About AxoGen Stock (NASDAQ:AXGN)

Key Stats

Today's Range
$15.88
$16.47
50-Day Range
$9.79
$16.26
52-Week Range
$9.22
$21.00
Volume
1.94 million shs
Average Volume
1.72 million shs
Market Capitalization
$742.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.00
Consensus Rating
Buy

Company Overview

AxoGen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
49th Percentile Overall Score

AXGN MarketRank™: 

AxoGen scored higher than 49% of companies evaluated by MarketBeat, and ranked 583rd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    AxoGen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    AxoGen has received no research coverage in the past 90 days.

  • Read more about AxoGen's stock forecast and price target.
  • Earnings Growth

    Earnings for AxoGen are expected to grow in the coming year, from ($0.29) to ($0.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of AxoGen is -161.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of AxoGen is -161.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    AxoGen has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about AxoGen's valuation and earnings.
  • Percentage of Shares Shorted

    9.17% of the float of AxoGen has been sold short.
  • Short Interest Ratio / Days to Cover

    AxoGen has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AxoGen has recently increased by 32.69%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    AxoGen does not currently pay a dividend.

  • Dividend Growth

    AxoGen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.17% of the float of AxoGen has been sold short.
  • Short Interest Ratio / Days to Cover

    AxoGen has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in AxoGen has recently increased by 32.69%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    AxoGen has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.05 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for AxoGen this week, compared to 4 articles on an average week.
  • Search Interest

    6 people have searched for AXGN on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added AxoGen to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, AxoGen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.78% of the stock of AxoGen is held by insiders.

  • Percentage Held by Institutions

    80.29% of the stock of AxoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about AxoGen's insider trading history.
Receive AXGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AxoGen and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AXGN Stock News Headlines

FDA Extends Review for AxoGen’s Avance Nerve Graft
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
New Banking Law #1582 Could Unlock $21 Trillion for Americans
Do you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. If you do…tc pixel
Lake Street Reaffirms Their Buy Rating on AxoGen (AXGN)
Raymond James Sticks to Their Buy Rating for AxoGen (AXGN)
FDA Pushes Back Axogen Avance Nerve Graft Decision By 3 Months
See More Headlines

AXGN Stock Analysis - Frequently Asked Questions

AxoGen's stock was trading at $16.48 at the beginning of the year. Since then, AXGN shares have decreased by 2.1% and is now trading at $16.14.

AxoGen, Inc. (NASDAQ:AXGN) announced its quarterly earnings data on Tuesday, November, 2nd. The medical equipment provider reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.05. The medical equipment provider earned $31.20 million during the quarter, compared to analyst estimates of $34.65 million. AxoGen had a negative net margin of 2.29% and a negative trailing twelve-month return on equity of 4.43%.

AxoGen's top institutional investors include First Light Asset Management LLC (9.84%), Balyasny Asset Management L.P. (4.20%), Soleus Capital Management L.P. (3.17%) and Wasatch Advisors LP (3.12%). Insiders that own company stock include Karen L Zaderej, Gregory Gene Freitag, Erick Wayne Devinney, Amy Mcbride Wendell, Guido J Neels, Peter J Mariani, Michael Patrick Donovan, Joseph A Tyndall and William P Mr Burke.
View institutional ownership trends
.

Shares of AXGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that AxoGen investors own include American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH), AU Optronics (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
11/02/2021
Today
8/30/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED INSTRUMENTS
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:AXGN
CIK
805928
Employees
450
Year Founded
2002

Price Target and Rating

High Price Target
$30.00
Low Price Target
$24.00
Potential Upside/Downside
+61.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.10)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$9.96 million
Net Margins
-2.29%
Pretax Margin
-2.29%
Return on Equity
-4.43%
Return on Assets
-2.34%

Debt

Debt-to-Equity Ratio
0.59
Current Ratio
4.14
Quick Ratio
2.67

Sales & Book Value

Annual Sales
$187.34 million
Price / Sales
3.96
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.44 per share
Price / Book
6.61

Miscellaneous

Outstanding Shares
46,010,000
Free Float
44,734,000
Market Cap
$742.60 million
Optionable
Optionable
Beta
1.00

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:AXGN) was last updated on 8/30/2025 by MarketBeat.com Staff
From Our Partners